

Mark A Preston

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11567454/publications.pdf>

Version: 2024-02-01

116
papers

2,898
citations

159358

30
h-index

182168

51
g-index

117
all docs

117
docs citations

117
times ranked

4795
citing authors

#	ARTICLE	IF	CITATIONS
1	A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with ¹⁸ F-DCFPyL in Prostate Cancer Patients (OSPREY). <i>Journal of Urology</i> , 2021, 206, 52-61.	0.2	180
2	Robot-assisted Versus Open Radical Prostatectomy: A Contemporary Analysis of an All-payer Discharge Database. <i>European Urology</i> , 2016, 70, 837-845.	0.9	178
3	Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. <i>Journal of Clinical Oncology</i> , 2016, 34, 3655-3663.	0.8	174
4	Neoadjuvant chemotherapy prior to radical cystectomy for muscle-invasive bladder cancer with variant histology. <i>Cancer</i> , 2017, 123, 4346-4355.	2.0	138
5	Comparative Effectiveness of Trimodal Therapy Versus Radical Cystectomy for Localized Muscle-invasive Urothelial Carcinoma of the Bladder. <i>European Urology</i> , 2017, 72, 483-487.	0.9	110
6	Metformin Use and Prostate Cancer Risk. <i>European Urology</i> , 2014, 66, 1012-1020.	0.9	109
7	Genome-wide association study identifies multiple risk loci for renal cell carcinoma. <i>Nature Communications</i> , 2017, 8, 15724.	5.8	106
8	Effectiveness of Adjuvant Chemotherapy After Radical Nephroureterectomy for Locally Advanced and/or Positive Regional Lymph Node Upper Tract Urothelial Carcinoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 852-860.	0.8	104
9	Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 439-439.	0.8	101
10	Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy. <i>JAMA Oncology</i> , 2016, 2, 500.	3.4	94
11	Testicular Cancer: What the Radiologist Needs to Know. <i>American Journal of Roentgenology</i> , 2013, 200, 1215-1225.	1.0	87
12	Micropapillary Urothelial Carcinoma of the Bladder: A Systematic Review and Meta-analysis of Disease Characteristics and Treatment Outcomes. <i>European Urology</i> , 2019, 75, 649-658.	0.9	82
13	Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 2705-2711.	0.8	74
14	Efficacy of High-Intensity Local Treatment for Metastatic Urothelial Carcinoma of the Bladder: A Propensity Score-Weighted Analysis From the National Cancer Data Base. <i>Journal of Clinical Oncology</i> , 2016, 34, 3529-3536.	0.8	70
15	Primary spermatic cord tumors: Disease characteristics, prognostic factors, and treatment outcomes. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 52.e19-52.e25.	0.8	68
16	Effectiveness of adjuvant chemotherapy after radical nephroureterectomy for locally advanced and/or positive regional lymph node upper tract urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 305-305.	0.8	63
17	Variations in the Costs of Radical Cystectomy for Bladder Cancer in the USA. <i>European Urology</i> , 2018, 73, 374-382.	0.9	62
18	Effectiveness of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer in the Current Real World Setting in the USA. <i>European Urology Oncology</i> , 2018, 1, 83-90.	2.6	59

#	ARTICLE	IF	CITATIONS
19	A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma. <i>British Journal of Cancer</i> , 2020, 122, 555-563.	2.9	59
20	The association between nerve sparing and a positive surgical margin during radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 18.e1-18.e6.	0.8	55
21	Regular Aspirin Use and the Risk of Lethal Prostate Cancer in the Physiciansâ€™ Health Study. <i>European Urology</i> , 2017, 72, 821-827.	0.9	44
22	Type 2 Diabetes in Relation to the Risk of Renal Cell Carcinoma Among Men and Women in Two Large Prospective Cohort Studies. <i>Diabetes Care</i> , 2018, 41, 1432-1437.	4.3	43
23	Baseline Prostate-specific Antigen Level in Midlife and Aggressive Prostate Cancer in Black Men. <i>European Urology</i> , 2019, 75, 399-407.	0.9	43
24	Evaluating the cost of surveillance for non-muscle-invasive bladder cancer: an analysis based on risk categories. <i>World Journal of Urology</i> , 2019, 37, 2059-2065.	1.2	40
25	Suicide and accidental deaths among patients with non-metastatic prostate cancer. <i>BJU International</i> , 2016, 118, 286-297.	1.3	39
26	Genetic Variants Related to Longer Telomere Length are Associated with Increased Risk of Renal Cell Carcinoma. <i>European Urology</i> , 2017, 72, 747-754.	0.9	39
27	5 α -Reductase Inhibitors and Risk of High-Grade or Lethal Prostate Cancer. <i>JAMA Internal Medicine</i> , 2014, 174, 1301.	2.6	38
28	The Effect of Resident Involvement on Perioperative Outcomes in Transurethral Urologic Surgeries. <i>Journal of Surgical Education</i> , 2015, 72, 1018-1025.	1.2	36
29	Prophylactic Antibiotics and Postoperative Complications of Radical Cystectomy: A Population Based Analysis in the United States. <i>Journal of Urology</i> , 2017, 198, 297-304.	0.2	35
30	The association of diabetes with risk of prostate cancer defined by clinical and molecular features. <i>British Journal of Cancer</i> , 2020, 123, 657-665.	2.9	31
31	Clinical features of leiomyosarcoma of the urinary bladder: Analysis of 183 cases. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 958-965.	0.8	30
32	Associations of specific postoperative complications with costs after radical cystectomy. <i>BJU International</i> , 2018, 121, 428-436.	1.3	30
33	Sex specific associations in genome wide association analysis of renal cell carcinoma. <i>European Journal of Human Genetics</i> , 2019, 27, 1589-1598.	1.4	27
34	Active surveillance for low-risk prostate cancer: Need for intervention and survival at 10 years. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 383.e9-383.e16.	0.8	24
35	Bladder cancer local staging: multiparametric MRI performance following transurethral resection. <i>Abdominal Radiology</i> , 2018, 43, 2412-2423.	1.0	22
36	Temporal trends in receipt of adequate lymphadenectomy in bladder cancer 1988 to 2010. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 504.e9-504.e17.	0.8	21

#	ARTICLE	IF	CITATIONS
37	The effect of treatment at minority-serving hospitals on outcomes for bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 238.e7-238.e17.	0.8	21
38	Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. <i>European Urology</i> , 2018, 73, 262-270.	0.9	20
39	Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?. <i>Cancer</i> , 2019, 125, 1319-1329.	2.0	20
40	Meat, Fish, Poultry, and Egg Intake at Diagnosis and Risk of Prostate Cancer Progression. <i>Cancer Prevention Research</i> , 2016, 9, 933-941.	0.7	18
41	Diagnosis of Bladder Carcinoma. <i>Surgical Pathology Clinics</i> , 2015, 8, 677-685.	0.7	17
42	Role of imaging in testicular cancer: Current and future practice. <i>Future Oncology</i> , 2015, 11, 2575-2586.	1.1	17
43	Effect of Nonurothelial Histologic Variants on the Outcomes of Radical Cystectomy for Nonmetastatic Muscle-invasive Urinary Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e129-e139.	0.9	17
44	Examining the relationship between complications and perioperative mortality following radical cystectomy: a population-based analysis. <i>BJU International</i> , 2019, 124, 40-46.	1.3	17
45	Active Surveillance of Prostate Cancer is a Viable Option for Men Younger than 60 Years. <i>Journal of Urology</i> , 2019, 201, 721-727.	0.2	15
46	Dietary Acrylamide Intake and Risk of Renal Cell Carcinoma in Two Large Prospective Cohorts. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 979-982.	1.1	13
47	Perioperative outcomes after radical cystectomy at NCI-designated centres: Are they any better?. <i>Canadian Urological Association Journal</i> , 2015, 9, 207.	0.3	13
48	Characterizing trends in treatment modalities for localized muscle-invasive bladder cancer in the pre-immunotherapy era. <i>World Journal of Urology</i> , 2018, 36, 1767-1774.	1.2	12
49	Durvalumab as neoadjuvant therapy for muscle-invasive bladder cancer: Preliminary results from the Bladder Cancer Signal Seeking Trial (BLASST)-2. <i>Journal of Clinical Oncology</i> , 2020, 38, 507-507.	0.8	12
50	Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. <i>European Urology</i> , 2022, 81, 466-473.	0.9	12
51	Contemporary Survival Rates for Muscle-Invasive Bladder Cancer Treated With Definitive or Non-Definitive Therapy. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e488-e493.	0.9	11
52	Aspirin Use and Lethal Prostate Cancer in the Health Professionals Follow-up Study. <i>European Urology Oncology</i> , 2019, 2, 126-134.	2.6	11
53	A prospective phase II/III multicenter study of PSMA-targeted 18F-DCFPyL PET/CT imaging in patients with prostate cancer (OSPREY): A sub-analysis of regional and distant metastases detection rates at initial staging by 18F-DCFPyL PET/CT. <i>Journal of Clinical Oncology</i> , 2020, 38, 9-9.	0.8	10
54	New Trends in the Surgical Management of Invasive Bladder Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2015, 29, 253-269.	0.9	9

#	ARTICLE	IF	CITATIONS
55	Positive Surgical Margins After Radical Prostatectomy: Does It Matter?. <i>European Urology</i> , 2014, 65, 314-315.	0.9	8
56	The Contemporary Incidence and Sequelae of Rhabdomyolysis Following Extirpative Renal Surgery: A Population Based Analysis. <i>Journal of Urology</i> , 2016, 195, 399-405.	0.2	8
57	Implementation of a Perioperative Venous Thromboembolism Prophylaxis Program for Patients Undergoing Radical Cystectomy on an Enhanced Recovery After Surgery Protocol. <i>European Urology Focus</i> , 2020, 6, 74-80.	1.6	8
58	Obesity in Relation to Renal Cell Carcinoma Incidence and Survival in Three Prospective Studies. <i>European Urology</i> , 2022, 82, 247-251.	0.9	8
59	Results of a phase II trial of intense androgen deprivation therapy prior to radical prostatectomy (RP) in men with high-risk localized prostate cancer (PC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 5503-5503.	0.8	7
60	Biomarker analysis and updated clinical follow-up from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in patients with muscle-invasive bladder cancer (MIBC) undergoing cystectomy.. <i>Journal of Clinical Oncology</i> , 2022, 40, 528-528.	0.8	7
61	Patterns of Recurrence in Upper Tract Transitional Cell Carcinoma: Imaging Surveillance. <i>American Journal of Roentgenology</i> , 2016, 207, 789-796.	1.0	6
62	Multilevel Analysis of Readmissions After Radical Cystectomy for Bladder Cancer in the USA: Does the Hospital Make a Difference?. <i>European Urology Oncology</i> , 2019, 2, 349-354.	2.6	6
63	Alvimopan Is Associated With a Reduction in Length of Stay and Hospital Costs for Patients Undergoing Radical Cystectomy. <i>Urology</i> , 2020, 140, 115-121.	0.5	6
64	Quality Improvement Efforts in Radical Cystectomy: From Prehab to Rehab. <i>European Urology</i> , 2018, 73, 372-373.	0.9	5
65	Inferior Cancer Survival for Men with Localized High-grade Prostate Cancer but Low Prostate-specific Antigen. <i>European Urology</i> , 2020, 78, 637-639.	0.9	5
66	Genomic landscape of variant urinary tumor histologies.. <i>Journal of Clinical Oncology</i> , 2021, 39, 467-467.	0.8	4
67	The impact of body mass index (BMI) on treatment outcome of targeted therapy in metastatic renal cell carcinoma (mRCC): Results from the International Metastatic Renal Cell Cancer Database Consortium.. <i>Journal of Clinical Oncology</i> , 2014, 32, 4576-4576.	0.8	4
68	A prospective phase 2/3 multicenter study of ¹⁸ F-DCFPyL PET/CT imaging in patients with prostate cancer: Examination of diagnostic accuracy (OSPNEY).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS5092-TPS5092.	0.8	4
69	Diagnostic tests in urology: magnetic resonance imaging (¹MRI</sup>) for the staging of prostate cancer. <i>BJU International</i> , 2013, 111, 514-517.	1.3	3
70	Clinical characterization of radiation-associated muscle-invasive bladder cancer. <i>Urology</i> , 2021, 154, 208-214.	0.5	3
71	Diagnostic performance of ¹⁸ F-DCFPyL in the OSPNEY Trial: A prospective phase 2/3 multicenter study of ¹⁸ F-DCFPyL PET/CT imaging in patients (Pts) with known or suspected metastatic prostate cancer (mPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 5012-5012.	0.8	3
72	5-alpha reductase inhibitors and prostate cancer mortality among men with regular access to screening and health care. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, , .	1.1	3

#	ARTICLE	IF	CITATIONS
73	Reply from Authors re: David Margel. Metformin to Prevent Prostate Cancer: A Call to Unite. Eur Urol 2014;66:1021-1022. European Urology, 2014, 66, 1022-1023.	0.9	2
74	Enrichment of FGFR3-TACC3 Fusions in Patients With Bladder Cancer Who Are Young, Asian, or Have Never Smoked. JCO Precision Oncology, 2018, 2, 1-11.	1.5	2
75	Contemporary perceptions of human papillomavirus and penile cancer: Perspectives from a national survey. Canadian Urological Association Journal, 2018, 13, 32-37.	0.3	2
76	Is Vasectomy a Cause of Prostate Cancer?. Journal of the National Cancer Institute, 2020, 112, 5-6.	3.0	2
77	A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPNEY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.. Journal of Clinical Oncology, 2021, 39, 32-32.	0.8	2
78	Reply by Authors. Journal of Urology, 2021, 206, 61-61.	0.2	2
79	Association between Operative Time and Short-Term Radical Cystectomy Complications. Urologia Internationalis, 2023, 107, 273-279.	0.6	2
80	Moving Towards Widespread Implementation of Enhanced Recovery Protocols for Radical Cystectomy. European Urology, 2016, 70, 1004-1005.	0.9	1
81	Reply to Aditya Bagrodia, Solomon Woldu, David F. Penson, Alexander Kutikov, and Samuel D. Kaffenberger's Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262-270. European Urology, 2018, 73, e100-e101.	0.9	1
82	Delayed blood transfusion is associated with mortality following radical cystectomy. Scandinavian Journal of Urology, 2020, 54, 290-296.	0.6	1
83	The impact of histological variants on bladder cancer survival: A population-based analysis.. Journal of Clinical Oncology, 2016, 34, 458-458.	0.8	1
84	Impact of variant histology on disease-specific mortality and survival in patients with non-muscle invasive bladder cancer (NMIBC): A population-based analysis.. Journal of Clinical Oncology, 2017, 35, 332-332.	0.8	1
85	Predicting the Gleason sum of a patient with a prostate biopsy core Gleason ≥ 7 and a prostate biopsy core Gleason ≤ 8 . Canadian Urological Association Journal, 2014, 8, 476.	0.3	0
86	Editorial Comment. Journal of Urology, 2017, 197, 1075-1075.	0.2	0
87	Reply to Christian D. Fankhauser, Nico C. Grossmann, Joerg Beyer, and Thomas Hermanns's Letter to the Editor re: Sophia C. Kamran, Thomas Seisen, Sarah C. Markt, et al. Contemporary Treatment Patterns and Outcomes for Clinical Stage IS Testicular Cancer. Eur Urol 2018;73:262-270.. European Urology, 2018, 73, e96-e97.	0.9	0
88	AUTHOR REPLY. Urology, 2020, 140, 121.	0.5	0
89	Impact of angiotensin inhibitors on pathologic complete response with neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC).. Journal of Clinical Oncology, 2021, 39, 432-432.	0.8	0
90	A prospective phase 2/3 study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPNEY): A sub-analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging.. Journal of Clinical Oncology, 2021, 39, e17003-e17003.	0.8	0

#	ARTICLE	IF	CITATIONS
91	The association between obesity and incidence of total and fatal renal cell carcinoma in two prospective cohorts.. Journal of Clinical Oncology, 2015, 33, 414-414.	0.8	0
92	Prevalence of non-recommended screening for prostate cancer and breast cancer in the United States.. Journal of Clinical Oncology, 2015, 33, e17528-e17528.	0.8	0
93	Regular aspirin use and the risk of lethal prostate cancer in the Physicians' Health Study.. Journal of Clinical Oncology, 2016, 34, 306-306.	0.8	0
94	Analgesic use and risk of renal cell cancer: Results from two prospective cohort studies.. Journal of Clinical Oncology, 2016, 34, 588-588.	0.8	0
95	Racial disparities in quality metrics of muscle invasive bladder cancer (MIBC).. Journal of Clinical Oncology, 2016, 34, 442-442.	0.8	0
96	Post-orchietomy adjuvant therapy versus surveillance for stage IS testicular cancer.. Journal of Clinical Oncology, 2017, 35, 406-406.	0.8	0
97	Is neoadjuvant chemotherapy beneficial before radical cystectomy? Examining the external validity of the SWOG-8710 trial.. Journal of Clinical Oncology, 2017, 35, 331-331.	0.8	0
98	Characterizing the costs of complications after cystectomy: Can we target the primary drivers?. Journal of Clinical Oncology, 2017, 35, 304-304.	0.8	0
99	Outcomes of elderly patients with muscle invasive bladder cancer (MIBC) treated with cystectomy or radiation therapy (RT): A surveillance epidemiology and end results (SEER) database analysis.. Journal of Clinical Oncology, 2017, 35, e16001-e16001.	0.8	0
100	Statin use and risk of renal cell carcinoma in three prospective cohort studies.. Journal of Clinical Oncology, 2018, 36, 679-679.	0.8	0
101	Dietary acrylamide intake and risk of renal cell carcinoma in two large prospective cohorts.. Journal of Clinical Oncology, 2018, 36, 677-677.	0.8	0
102	The prognostic impact of a negative confirmatory biopsy in men on active surveillance for prostate cancer.. Journal of Clinical Oncology, 2018, 36, 76-76.	0.8	0
103	FGFR3-TACC3 fusion in bladder cancer: Enrichment in the young, never-smokers, and Asians.. Journal of Clinical Oncology, 2018, 36, 465-465.	0.8	0
104	The impact of treatment at minority-serving hospitals on outcomes for bladder cancer.. Journal of Clinical Oncology, 2018, 36, 492-492.	0.8	0
105	Model combining genomic and clinical factors to predict clinical benefit from PD1/PD-L1 inhibitors for advanced UC.. Journal of Clinical Oncology, 2018, 36, 4539-4539.	0.8	0
106	Genomic profiling of variant urinary tract tumor histologies.. Journal of Clinical Oncology, 2019, 37, 450-450.	0.8	0
107	Neoadjuvant chemotherapy for muscle-invasive bladder cancer: Dana-Farber Cancer Institute (DFCI) experience.. Journal of Clinical Oncology, 2019, 37, e16037-e16037.	0.8	0
108	Resource utilization and cost efficacy analysis of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (DD-MVAC) versus gemcitabine-cisplatin (GC) as neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC).. Journal of Clinical Oncology, 2020, 38, e19390-e19390.	0.8	0

#	ARTICLE	IF	CITATIONS
109	Impact of histology and toxicities on outcomes of patients with muscle invasive bladder cancer receiving neoadjuvant chemotherapy.. Journal of Clinical Oncology, 2020, 38, 540-540.	0.8	0
110	5-alpha reductase inhibitors (5-ARI) and prostate cancer mortality among men with regular access to screening and health care.. Journal of Clinical Oncology, 2020, 38, 39-39.	0.8	0
111	Impact of MRI on outcomes in active surveillance (AS) for localized prostate cancer in a hospital registry.. Journal of Clinical Oncology, 2020, 38, 280-280.	0.8	0
112	Resource utilization analysis of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (DD-MVAC) versus gemcitabine-cisplatin (GC) as neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer (MIBC).. Journal of Clinical Oncology, 2020, 38, 474-474.	0.8	0
113	Impact of angiotensin-converting enzyme inhibitors (ACEi) on pathologic complete response with neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (MIBC).. Journal of Clinical Oncology, 2022, 40, 485-485.	0.8	0
114	Time trends of overall survival and other outcomes in patients with mHSPC: An observational study of U.S. EHR data (TIMES).. Journal of Clinical Oncology, 2022, 40, e17051-e17051.	0.8	0
115	Open-label study of androgen receptor inhibition with darolutamide plus androgen-deprivation therapy (ADT) versus ADT in men with metastatic hormone-sensitive prostate cancer using an external control arm (ARASEC).. Journal of Clinical Oncology, 2022, 40, TPS5111-TPS5111.	0.8	0
116	Abstract 5893: Analgesic use and renal cell carcinoma incidence and survival: Results from three prospective cohort studies. Cancer Research, 2022, 82, 5893-5893.	0.4	0